New study explores Kidney-Friendly hepatitis b drug for transplant patients

NCT ID NCT07267208

Not yet recruiting Disease control Sponsor: Jongman Kim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial will enroll 82 stable liver transplant recipients with chronic hepatitis B to see if switching to entecavir orally disintegrating tablets (ETV-ODT) is safe and helps preserve kidney function. Participants will take the drug daily for 48 weeks, and researchers will monitor changes in kidney function and any signs of hepatitis B returning. The study aims to offer a more convenient treatment option that may be gentler on the kidneys.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Entecavir orally disintegrating tablets (ETV-ODT)
What this could lead to: If successful, this could show that switching to entecavir ODT is safe and may help protect kidney function in liver transplant patients with hepatitis B.
What could go wrong: This is a small, early-phase study with only 82 participants, so results may not apply to all patients. It focuses on kidney function, not on curing hepatitis B, and there is a risk of HBV recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B VIRUS LIVER TRANSPLANT

More trials for these conditions

Other studies related to the condition(s) this trial covers.